Janssen Research & Development, LLC Clinical trials

Trials

Studies that name Janssen Research & Development, LLC Clinical trials as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:13 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT04782661 · A Study of JNJ-70075200 in Healthy Participants

  Janssen Research & Development, LLC · withdrawn · Healthy · study director
• Ph1
  NCT04661397 · A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

  Janssen Research & Development, LLC · completed · Healthy · study director
• Ph3
  NCT04658862 · A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  Janssen Research & Development, LLC · active not recruiting · Urinary Bladder Neoplasms · study director
• Ph1
  NCT04657224 · A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  Janssen Research & Development, LLC · completed · Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia · study director
• Ph2
  NCT04264806 · A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  Janssen Research & Development, LLC · withdrawn · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic · study director
• Ph1
  NCT02659735 · A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

  Janssen Research & Development, LLC · completed · Influenza A Virus · study director
• N/A
  NCT02636192 · Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

  Janssen Research & Development, LLC · completed · Diabetes Mellitus, Type 2 · study director
• N/A
  NCT02489305 · Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)

  Janssen Research & Development, LLC · completed · Depressive Disorder, Major · study director
• Ph1
  NCT02381080 · Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

  Janssen Research & Development, LLC · completed · B-Cell Chronic Lymphocytic Leukemia · study director
• Ph1
  NCT02231489 · Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

  Janssen Research & Development, LLC · completed · Healthy · study director
• N/A
  NCT02155192 · An Exploratory Genetic Study in Participants With Psoriasis

  Janssen Research & Development, LLC · completed · Psoriasis · study director
• Ph1
  NCT02152332 · A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

  Janssen Research & Development, LLC · completed · Healthy · study director
• Ph1
  NCT02127593 · A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities

  Janssen Research & Development, LLC · completed · Healthy · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.